GABRIEL HABIB to Hypertension
This is a "connection" page, showing publications GABRIEL HABIB has written about Hypertension.
Connection Strength
0.555
-
Are there any new pharmacologic therapies on the horizon to better treat hypertension? A state-of-the-art paper. J Cardiovasc Pharmacol Ther. 2014 Nov; 19(6):516-25.
Score: 0.236
-
Are calcium antagonists harmful in hypertensive patients? Distinguishing hype from reality. Chest. 1995 Jul; 108(1):3-5.
Score: 0.064
-
Characteristics and long-term follow-up of participants with peripheral arterial disease during ALLHAT. J Gen Intern Med. 2014 Nov; 29(11):1475-83.
Score: 0.061
-
Stroke outcomes among participants randomized to chlorthalidone, amlodipine or lisinopril in ALLHAT. J Am Soc Hypertens. 2014 Nov; 8(11):808-19.
Score: 0.060
-
Mortality and morbidity during and after Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial: results by sex. Hypertension. 2013 May; 61(5):977-86.
Score: 0.055
-
Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril. JAMA. 2005 Apr 06; 293(13):1595-608.
Score: 0.031
-
Cardiovascular outcomes using doxazosin vs. chlorthalidone for the treatment of hypertension in older adults with and without glucose disorders: a report from the ALLHAT study. J Clin Hypertens (Greenwich). 2004 Mar; 6(3):116-25.
Score: 0.029
-
Reappraisal of the importance of heart rate as a risk factor for cardiovascular morbidity and mortality. Clin Ther. 1997; 19 Suppl A:39-52.
Score: 0.018